Standout Papers
Citation Impact
Citing Papers
Combinations of DNA Methyltransferase and Histone Deacetylase Inhibitors Induce DNA Damage in Small Cell Lung Cancer Cells: Correlation of Resistance with IFN-Stimulated Gene Expression
2010
Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study
2012
Retinoblastoma-binding protein 2 (RBP2) is frequently expressed in neuroendocrine tumors and promotes the neoplastic phenotype
2016
Epidemiology, risk factors, and lifestyle modifications for gout.
2006
Serum uric acid and cardiovascular disease: Recent developments, and where do they leave us?
2005
Functions of DNA methylation: islands, start sites, gene bodies and beyond
2012 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Targeting cancer stem cell pathways for cancer therapy
2020
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
2010
Lack of Association Between Serum Uric Acid and Organ Damage in a Never-Treated Essential Hypertensive Population at Low Prevalence of Hyperuricemia
2007
Therapeutic modulation of Notch signalling — are we there yet?
2014
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
2013 Standout
Influence of Metabolism on Epigenetics and Disease
2013 StandoutNobel
Telomeres: history, health, and hallmarks of aging
2021
Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application
2014
The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
2011 Standout
The emerging role of lncRNAs in cancer
2015 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Hallmarks of aging: An expanding universe
2023 Standout
Shaping human telomeres: from shelterin and CST complexes to telomeric chromatin organization
2021 Nobel
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Uric Acid and Cardiovascular Risk
2008 Standout
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
2015
Lung cancer: New biological insights and recent therapeutic advances
2011
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
Cancer stem cells revisited
2017 Standout
Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis
2012
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Gout
2009 Standout
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
Biological Functions of Autophagy Genes: A Disease Perspective
2019 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Plasma Uric Acid Level and Risk for Incident Hypertension Among Men
2006
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
2017 Standout
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings
2008
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Epigenetic treatment of solid tumours: a review of clinical trials
2015
Gout
2016 Standout
Programmed Death 1 Pathway inhibition in Metastatic Renal Cell Cancer and Prostate Cancer
2012
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
2016
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
TET enzymes, TDG and the dynamics of DNA demethylation
2013 StandoutNature
Uric acid: A marker of increased cardiovascular risk
2008
IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage
2013 StandoutNobel
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Cardiovascular Complications of Cancer Therapy
2009
Structure-based optimization of click-based histone deacetylase inhibitors
2011
Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin–angiotensin system
2008
The many roles of histone deacetylases in development and physiology: implications for disease and therapy
2008 Standout
FOXP3+ regulatory T cells in the human immune system
2010 StandoutNobel
Tackling the cancer stem cells — what challenges do they pose?
2014
A decade of exploring the cancer epigenome — biological and translational implications
2011 Standout
Uricosuric Action of Losartan via the Inhibition of Urate Transporter 1 (URAT 1) in Hypertensive Patients
2008
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase
2018 StandoutNobel
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Click Chemistry for Drug Development and Diverse Chemical–Biology Applications
2013 Standout
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
2009 Standout
Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
2012
Histone Deacetylase Inhibitors as Anticancer Drugs
2017
Chronic Kidney Disease Diagnosis and Management
2019 Standout
Head and Neck Cancer
2020 Standout
The Tumor Lysis Syndrome
2011 Standout
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.
2011
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment
2014
The role of B7 family molecules in hematologic malignancy
2012
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
2012
New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice
2014
Gout
2021 Standout
Serum Uric Acid Is Associated With Microalbuminuria in Prehypertension
2006
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
2007 Standout
PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
2015
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
2017 Standout
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
2015 Standout
Neoantigens in cancer immunotherapy
2015 StandoutScience
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update
2020 Standout
A Review of ULK1-Mediated Autophagy in Drug Resistance of Cancer
2020
Multiple Myeloma
2011 Standout
Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis
2013
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Works of Cong Chen being referenced
Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma
2007 Standout
Structural insights into POT1-TPP1 interaction and POT1 C-terminal mutations in human cancer
2017
The impact of serum uric acid on cardiovascular outcomes in the LIFE study
2004
Diagnostic Accuracy of Computer Tomography Angiography and Magnetic Resonance Angiography in the Stenosis Detection of Autologuous Hemodialysis Access: A Meta-Analysis
2013
Evaluation of the Long-Term Tolerability and Clinical Benefit of Vorinostat in Patients With Advanced Cutaneous T-Cell Lymphoma
2009
Anti−IL-12/23 p40 antibody attenuates chronic graft-versus-host disease with lupus nephritis via inhibiting Tfh cell in mice
2020
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
2008
The crosstalk between autophagy and ferroptosis: what can we learn to target drug resistance in cancer?
2019
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
2007
Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Combination with Bortezomib in Patients with Advanced Multiple Myeloma.
2007
Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors
2012
Tumor-Associated Macrophages Regulate Murine Breast Cancer Stem Cells Through a Novel Paracrine EGFR/Stat3/Sox-2 Signaling Pathway
2012
Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors.
2012